Compare GDDY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDDY | PTGX |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | 141 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 9.3B |
| IPO Year | 2014 | 2016 |
| Metric | GDDY | PTGX |
|---|---|---|
| Price | $96.71 | $138.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | ★ $136.44 | $108.23 |
| AVG Volume (30 Days) | ★ 1.8M | 498.6K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.43 | 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $7.94 | $874.25 |
| Revenue Next Year | $6.10 | N/A |
| P/E Ratio | ★ $28.64 | $61.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.59 | $62.24 |
| 52 Week High | $143.34 | $160.81 |
| Indicator | GDDY | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.01 |
| Support Level | N/A | $141.95 |
| Resistance Level | N/A | $151.24 |
| Average True Range (ATR) | 0.00 | 4.49 |
| MACD | 0.00 | -0.52 |
| Stochastic Oscillator | 0.00 | 42.25 |
GoDaddy Inc provides digital solutions and services for entrepreneurs, small businesses, individuals, organizations, developers, designers, and domain investors. It offers tools intended to support business creation and management through an integrated service platform. The company operates through two segments: Applications and Commerce (A&C) and Core Platform (Core). The majority of the company's revenue is derived from the Core Platform segment, which consists of sales of domain registrations and renewals, aftermarket domain sales, website hosting products and website security products. Geographically, it generates the maximum revenue from the United States.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.